CRF Specification for Test Trial abcd

Lorem ipsum dolor sit amet consectetuer odio id et turpis vitae. Est risus congue pretium non Vestibulum ante dui risus Nam convallis. Semper vitae Sed lacus pretium ut tortor tempus felis massa pellentesque. Congue a odio ut Aenean libero hendrerit eros cursus arcu quis. Urna velit consequat ipsum Sed Aliquam.

Protocol Name: Test Trial

CRF Creation date: 2020-05-07T12:44:01+02:00

Table of Contents

AE/CM/CP/Other events involving IMP Events

<u>Demographics</u>

Height and weight

<u>Urine pregnancy test</u>

Adverse event

Urine dipstick

Concomitant medication

Blood biomarkers

Concurrent procedures

Central laboratory

ECG

Desi trial: lega	CM/CP/Other events involving note: This form is only us, where a subject might real age that require them to sisent during the conduct of t	SDTM Annotation	
1.1	Did the subject have any adverse events since screening	○ Yes ○ No	NOT SUBMITTED
1.2	Did the subject take any concomitant medications?	○ Yes ○ No	NOT SUBMITTED
1.3	Did the subject have any concurrent procedures/surgeries since screening?	○ Yes ○ No	NOT SUBMITTED
1.4	Did the subject have any other events involving IMP since screening? Internal note: If the code Lack of efficacy is added to the item 'other event involving IMP' on the form 'other event involving IMP' then adjust the CRF guidance text accordingly	○ Yes ○ No	

Der	nographics	SDTM Annotation	
1.1	Date of birth	mm/dd/yyyy	BRTHDTC
2.1	Age		QVAL, SUPPDM.QNAM=AGEn. Set SUPPDM.QNAM=AGEnVIS where QVAL=the visit where age is collected
2.2	Age unit	○ Year(s)	QVAL, SUPPDM.QNAM=AGEnU n is a consequitive counter starting from 1
3.1	Sex	○ Male ○ Female	SEX
3.2	Ethnicity	○ Hispanic or Latino ○ Not Hispanic or Latino	ETHNIC
3.3	Race	 ○ White ○ Black or African American ○ Asian ○ American Indian or Alaska Native ○ Native Hawaiian or Other Pacific Islander ○ Other 	RACE, if RACE=OTHER then value is set to NULL
3.4	Race	 ○ White ○ Black or African American ○ Asian Japanese ○ Asian Other ○ American Indian or Alaska Native ○ Native Hawaiian or Other Pacific Islander ○ Other 	RACE, if RACE=OTHER then value is set to NULL. If one of the two Asian races are indicated, set RACE=ASIAN and store original value in SUPPDM.QNAM=RACEC
4.1	[If Other,]Specify		QVAL, SUPPDM.QNAM=RACEOTH

Hei	ght and weight	SDTM Annotation	
1.1	Height		VSORRES, VSTESTCD=HEIGHT
1.2	Unit height	○ cm ○ in	VSORRESU, VSTESTCD=HEIGHT
1.3	Weight		VSORRES, VSTESTCD=WEIGHT
1.4	Unit weight	○ kg ○ lb	VSORRESU, VSTESTCD=WEIGHT
1.5	Body Mass Index (BMI)		VSORRES, VSTESTCD=BMI
1.6	BMI unit	○kg/m2	VSORRESU, VSTESTCD=BMI

Urir	Urine pregnancy test		SDTM Annotation
1.1	Is the female of child- bearing potential?	○ Yes ○ No	RPORRES, RPTESTCD=CHILDPOT
1.2	[If Yes,]Was a urine pregnancy test performed?	○ Yes ○ No	RPORRES, RPTESTCD=HCGDONE. If No then PRSTAT=NOT DONE
1.3	[If No,]Specify reason		RPREASND
2.1	[If Yes,]Urine pregnancy test date	mm/dd/yyyy	LBDTC, LBCAT=URINALYSIS, LBTESTCD=HCG, LBSPEC=URINE, LBSPID=COLLECTED
2.2	[If Yes,]Result	○ Positive ○ Negative	LBORRES, LBCAT=URINALYSIS, LBTESTCD=HCG, LBSPEC=URINE, LBSPID=COLLECTED

Adverse event			SDTM Annotation
1.1	AE identifier		AESPID
2.1	Adverse event		AETERM
3.1	Location of AE relative to treatment area	 Non-cutaneous Lesional/perilesional Distant Inside treatment area Outside treatment area Application area 	QVAL, SUPPAE.QNAM=AERELTRT
4.1	Location of AE	○ NA (Non-cutaneous) ○ Back ○ Scalp ○ Face ○ Chest ○ Arm ○ Leg ○ Trunk ○ Limb ○ Site 1 ○ Site 2 ○ Site 3 ○ Site 4	AELOC, If value does not exist on LOC codelist then place in SUPPAE.QVAL where QNAM=ALTLOC.
4.2	Start date	mm/dd/yyyy	AESTDTC
5.1	If the adverse event started on the SAME DAY a dose was administered, did the adverse event start before or after dosing of IMP?	○ Before dosing○ After dosing○ Not applicable	QVAL, SUPPAE.QNAM=AEOCCUR

Adv	erse event		SDTM Annotation
5.2	Did the adverse event start before the first administration of IMP? Internal note: Used in e.g. AK trials and Test drug trials. Only one of the questions 'If the adverse event started on the SAME DAY a dose was administered, did the adverse event start before or after dosing of IMP?' or 'Did the adverse event start before the first administration of IMP?' is used. (tralokinumab/placebo) only to be added to question in trials where additional IMP's than the randomized treatment are included. Align the text in the brackets to the protocol. CRF Guidance text: Note the first administration = the administration at week O/Visit 3. Adjust CRF Guidance to protocol.	○ Yes ○ No	QVAL, SUPPAE.QNAM=AETRTEM
5.3	Did the adverse event start before the administration of the vaccines?	○ Yes ○ No	QVAL, SUPPAE.QNAM=AEOCCUR
6.1	Stop date Design note: Day can be unknown but month and year must be filled out	mm/dd/yyyy	AEENDTC
6.2	Ongoing	○ Yes ○ No	AEENRTPT, If ONGOING then AEENTPT=END OF TRIAL
6.3	Severity	○ Mild○ Moderate○ Severe	AESEV
6.4	Was the AE related to IMP?	○ Probably related○ Possibly related○ Not related	AEREL
6.5	Action taken with IMP	 ○ Dose not changed ○ Dose reduced ○ Dose increased ○ Drug interrupted ○ Drug withdrawn ○ Not applicable ○ Unknown 	AEACN

Adv	erse event	SDTM Annotation	
6.6	Was the AE related to AxMP (TCS)?	○ Probably related○ Possibly related○ Not related	AERELNST
7.1	Was the AE related to IMP (Tdap vaccine)?	○ Probably related○ Possibly related○ Not related	QVAL, SUPPAE.QNAM=RELTDAP
7.2	Was the AE related to IMP (meningococcal vaccine)? Internal note: Item only to be added in trials where additional IMP's than the randomized treatment are included. Align the text in the brackets to the protocol.	○ Probably related○ Possibly related○ Not related	QVAL, SUPPAE.QNAM=RELMENI
8.1	Did the AE start at the same day as CYP cocktail was given?	○ Yes ○ No	QVAL, SUPPAE.QNAM=CYPTRTEM
8.2	[if Yes,]Start time of AE	:	QVAL, SUPPAE.QNAM=AESTDTC
8.3	[If Yes,]Stop time of AE	:	QVAL, SUPPAE.QNAM=AEENDTC
9.1	Action taken with AxMP (TCS)	 ○ Dose not changed ○ Dose reduced ○ Dose increased ○ Drug interrupted ○ Drug withdrawn ○ Not applicable ○ Unknown 	QVAL, SUPPAE.QNAM=AEACNNST
10.1	Other action taken (tick all that apply)	□ None □ Concomitant medication □ Concurrent procedure	AEACNOTH, IF MULTIPLE ANSWERS ARE GIVEN SET AEACNOTH TO MULTIPLE AND STORE INDIVIDUAL ANSWERS IN SUPPAE
11.1	Withdrawn from trial due to this AE?	○ Yes ○ No	QVAL, SUPPAE.QNAM=AEAWDR
12.1	Was the AE serious?	○ Yes ○ No	AESER
13.1	SAE criteria (Tick all that apply)	☐ Death ☐ Life-threatening ☐ In-patient hospitalisation/prolongation of existing hospitalisation ☐ Persistent or significant disability/incapacity ☐ Congenital anomaly/birth defect ☐ Other medically important condition	If ticked, set the relevant variable in AE to Y. If Fatal, set AESDTH. If Life-threatening set AESLIFE. If Hospitalisation set AESHOSP.

Adv	erse event	SDTM Annotation	
14.1	Outcome	 ○ Fatal ○ Not recovered/not resolved ○ Recovering/resolving ○ Recovered/resolved ○ Recovered/resolved with sequelae ○ Unknown 	AEOUT
15.1	Is the event an adverse event of special interest?	○ Yes ○ No	QVAL, SUPPAE.QNAM=AESI

Urir	ne dipstick		SDTM Annotation
1.1	Was a urine sample tested with a dipstick?	○ Yes ○ No	LBORRES, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED, LBMETHOD=DIPSTICK. If No, then LBSTAT=NOT DONE and populate LBREASND. If Yes set LBORRES to Y.
1.2	[If No,]Specify reason		LBREASND, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED, LBMETHOD=DIPSTICK.
1.3	[If Yes,]Result	○ Normal ○ Abnormal	LBORRES, LBCAT=URINALYSIS, LBTESTCD=INTP, LBSPEC=URINE, LBSPID=COLLECTED, LBMETHOD=DIPSTICK.

Con	comitant medication		SDTM Annotation
1.1	CM Number		CMSPID
1.2	Medication or therapy (generic or brand name)		CMTRT
2.1	Is this medication or therapy a rescue medication for chronic hand eczema?	○ Yes ○ No	QVAL, SUPPCM.QNAM=RESCMED
3.1	Indication		CMINDC
3.2	Dose per administration		CMDOSTXT, If CMDOSTXT is a numeric value, then transfer the number to the numeric field CMDOSE, and set CMDOSTXT to null
3.3	Unit	 mcg mg g MI Application International Unit (IU) Tablet Capsule Other 	CMDOSU
4.1	[If Other,]Specify		QVAL, SUPPCM.QNAM = DOSUOTH
5.1	Frequency	 ○ As needed (PRN) ○ Daily (QD) ○ Twice daily (BID) ○ Three times per day (TID) ○ Four times per day ○ Weekly (QS) ○ Monthly (QM) ○ Once ○ Other 	CMDOSFRQ
6.1	[If Other,]Specify		QVAL, SUPPCM.QNAM = FRQOTH
7.1	Route	 ○ Oral ○ Topical ○ Subcutaneous ○ Transdermal ○ Intraocular ○ Intramuscular ○ Respiratory (inhalation) ○ Intralesional ○ Intraperitoneal ○ Nasal ○ Vaginal ○ Rectal ○ Intravenous ○ Other 	CMROUTE

Con	comitant medication	SDTM Annotation	
8.1	[If Topical,]Dose form	○ Cream○ Lotion○ Ointment○ Other	CMDOSFRM
9.1	[If Other,]Specify		QVAL, SUPPCM.QNAM=FRMOTH
10.1	Start date	mm/dd/yyyy	CMSTDTC
10.2	Stop date	mm/dd/yyyy	CMENDTC
10.3	Ongoing	○ Yes ○ No	CMENRTPT, CMENTPT=END OF TRIAL

Blo	Blood biomarkers		SDTM Annotation
1.1	Did the subject sign the additional informed consent for biomarkers?	○ Yes ○ No	DSDECOD, DSCAT=PROTOCOL MILESTONE. If No then create no record. If Yes then DSTERM=INFORMED CONSENT FOR ADDITIONAL BIOMARKERS, DSDECOD=INFORMED CONSENT OBTAINED
1.2	[If Yes,]Provide date the consent was signed	mm/dd/yyyy	DSSTDTC
2.1	Was sampling performed for blood biomarkers?	YesNoNot applicable	LBORRES, LBCAT=BIOMARKER, LBTESTCD=SAMPLE, LBSPEC=SERUM, LBSPID=COLLECTED. If No, then LBSTAT=NOT DONE, LBORRES and populate LBREASND. If Yes set LBORRES to Y. If NA set LBORRES to NA.
2.2	[If No,]Specify reason		LBREASND, LBCAT=BIOMARKER, LBTESTCD=SAMPLE, LBSPEC=SERUM, LBSPID=COLLECTED.

Concurrent procedures			SDTM Annotation	
1.1	Procedure number		PRSPID	
1.2	Procedure name (include anatomical area if relevant)	PRTRT		
1.3	Procedure name		PRTRT	
1.4	Indication		PRINDC	
1.5	Start date	mm/dd/yyyy	PRSTDTC	
1.6	Stop date	mm/dd/yyyy	PRENDTC	
1.7	Ongoing	○ Yes ○ No	PRENRTPT, PRENTPT=END OF TRIAL	
1.8	Body location	○ Head○ Trunk○ Upper limb○ Lower limb	PRLOC	
2.1	Inside treatment area?	○ Yes○ No○ Unknown○ Not applicable	QVAL, SUPPPR.QNAM=INTRTAR	

Central laboratory			SDTM Annotation
1.1	Was blood sampling performed?	○ Yes ○ No	LBORRES, LBCAT=BLOOD ANALYSIS, LBTESTCD=SAMPLE, LBSPEC=BLOOD, LBSPID=COLLECTED. If No, then LBSTAT=NOT DONE and populate LBREASND. If Yes set LBORRES to Y.
1.2	[If No,]Specify reason		LBREASND, LBCAT=BLOOD ANALYSIS, LBTESTCD=SAMPLE, LBSPEC=BLOOD, LBSPID=COLLECTED.
1.3	[If Yes,]Date of sampling	mm/dd/yyyy	LBDTC, LBCAT=BLOOD ANALYSIS, LBTESTCD=SAMPLE, LBSPEC=BLOOD, LBSPID=COLLECTED.
1.4	[If Yes,]Time of sampling	:	LBDTC, LBCAT=BLOOD ANALYSIS, LBTESTCD=SAMPLE, LBSPEC=BLOOD, LBSPID=COLLECTED.
1.5	[If Yes,]Result	○ Normal○ Abnormal, notclinically significant○ Abnormal, clinicallysignificant	LBORRES, LBCAT=BLOOD ANALYSIS, LBTESTCD=INTP, LBSPEC=BLOOD, LBSPID=COLLECTED. If Normal LBORRES=NORMAL, if Abnormal LBORRES=ABNORMAL.
1.6	Was a urine sample sent for urinalysis?	○ Yes○ No○ Not applicable	LBORRES, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED. If No, then LBSTAT=NOT DONE, LBORRES set as blank and populate LBREASND. If Yes set LBORRES to Y.
1.7	[If No,]Specify reason		LBREASND, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED.
1.8	[If Yes,]Date of sampling	mm/dd/yyyy	LBDTC, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED.
1.9	[If Yes,]Time of sampling	:	LBDTC, LBCAT=URINALYSIS, LBTESTCD=SAMPLE, LBSPEC=URINE, LBSPID=COLLECTED.

Central laboratory		SDTM Annotation	
1.10 [If Yes,]Result	○ Normal ○ Abnormal, not clinically significant ○ Abnormal, clinically significant	LBORRES, If Clinically Significant SUPPLB.QVAL=Y(QNAM=LBCLSIG),if Not Clinically significant SUPPLB.QVAL=N(QNAM=LBCLSIG)	

EC	G	SDTM Annotation	
1.1	Was the ECG performed?	○ Yes ○ No	EGORRES, EGTESTCD=INTP. If Yes then use EGORRES for the result. If No then EGSTAT=NOT DONE and populate EGREASND.
1.2	[If No,]Specify reason		EGREASND, EGTESTCD=INTP
1.3	Date of ECG	mm/dd/yyyy	EGDTC, EGTESTCD=INTP
1.4	[If Yes,]Results	○ Normal ○ Abnormal, not clinically significant ○ Abnormal, clinically significant	EGORRES, EGTESTCD=INTP. If Normal EGORRES= NORMAL, if Abnormal EGORRES= ABNORMAL. If Clinically Significant SUPPEG.QVAL=Y(QNAM=EGCLSIG), if Not Clinically significant SUPPEG.QVAL=N(QNAM=EGCLSIG)